(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD818,400. 20180808-HBP-Press-Release-Closes-Private-Placement-FINAL.pdf
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Safety Review Committee (“SRC”) reviewed safety data from the fourth dosing cohort of the Company’s LDOS001 study and recommended that Helix begin enrollment of […]
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD1,000,200. 20180709-HBP-Press-Release-Closes-Private-Placement-FINAL.pdf
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial results for its fiscal quarter ended April 30, 2018. Helix-Announces-Fiscal-Q3-2018-Results.pdf
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD940,800. Helix-Closes-Private-Placement.pdf
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Safety Review Committee (“SRC”) reviewed safety data from the third dosing cohort of the Company’s LDOS001 study and recommended that Helix begin enrollment of […]
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD605,400. 20180430-HBP-Press-Release-Closes-Private-Placement-FINAL.pdf
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that all necessary regulatory and ethics approvals have been received to dose the first patient in its LDOS003 trial in Ukraine. Regulatory approvals for […]
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the formation of the Scientific and Strategic Advisory Board (“SSAB”) with a renowned group of physicians and scientists. Members of the SSAB include Dr. Daniel […]
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), a immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the completion of the collaboration agreement with ProMab Biotechnologies, Inc. (“ProMab”) to develop novel antibody and chimeric antigen receptor T-cell therapy (“CAR-T”) for particular hematological […]